Viewing data from:

NIACIN

ANDA

NIACIN | A203742 | RISING PHARMA HOLDINGS INC

3 strengths0 unique patents0 unique exclusivities

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
AbbVie Inc. et al v. Mylan Inc. et al 1:2012cv00257 9 patentsANDA 203742niacin	D. Del.	2012-03-02	Terminated 2014-02-04	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

API Supply Chain4 active DMFs4 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

AURORIUM LLCNIACIN USP

DMF 82591989

DIVIS LABORATORIES LTDNIACIN USP

DMF 184812005

AARTI DRUGS LTDNIACIN

DMF 200512006

JUBILANT PHARMOVA LTDNIACIN USP

DMF 313822017

WOCKHARDT LTDInactiveNIACIN

DMF 76421988

LONZA AGInactiveNIACIN USP SPECIAL

DMF 80411989

LONZA LTDInactiveNIACIN USP GRANULAR SPECIAL

DMF 182932005

ABBVIE INCInactiveNIACIN CORE TABLET INTERMEDIATE

DMF 218762008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — 500MG

0 patents0 exclusivities▴

TABLET, EXTENDED RELEASE;ORAL | Approved: Feb 22, 2019

No patent or exclusivity listings for this strength.

#002 — 750MG

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Feb 22, 2019

#003 — 1GM

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Feb 22, 2019